Is treat-to-target really working in rheumatoid arthritis? a longitudinal analysis of a cohort of patients treated in daily practice (RA BIODAM)

Josef S Smolen ,Maurizio Rossini,Désirée Van Der Heijde,Cornelia F Allaart,Robert Landewé ,Joel Paschke,Alain Saraux,Cheryl Barnabé ,Joanne Homik,Thierry Schaeverbeke,Maggie Larché ,Gilles Boire,Gianfranco Ferraciolli,Paul P Tak ,R Dadashova ,Alexandre Sepriano,Ori Elkayam,Luigi Sinigaglia,Dirkjan Van Schaardenburg,Oliver Fitzgerald,A Cantagrel ,John Thorne ,Clifton O Bingham ,Marina Backhaus,Maxime Dougados,Mikkel Østergaard ,Bernard Combe,E Hutchings ,Hilde Berner Hammer,Marcello Govoni,Walter P Maksymowych

doi:10.1136/annrheumdis-2019-216819

Abstract

ObjectivesTo investigate whether following a treat-to-target (T2T)-strategy in daily clinical practice leads to more patients with rheumatoid arthritis (RA) meeting the remission target.MethodsRA patients from 10 countries starting/changing conventional synthetic...

Full Text